Drug Profile
BKT 300
Alternative Names: BKT-300Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Biokine Therapeutics
- Class Small molecules
- Mechanism of Action Protein-serine-threonine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Solid-tumours in Israel
- 09 Sep 2021 Biokine Therapeutics plans to file an IND application for Solid tumours in September 2022 (Biokine Therapeutics pipeline, September 2021)
- 08 Sep 2021 BKT 300 is still in preclinical trials for Solid tumours in Israel (Biokine's pipeline, September 2021)